Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis

CONCLUSION: Patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in ability to sustain remission, for up to 18 months. Longer follow-up studies with attention to radiographic, functional and patient-reported outcomes are needed. The risk of disease worsening should be discussed with the patient with careful follow-up and prompt retreatment of disease worsening.PMID:35970524 | DOI:10.3899/jrheum.220152

Source: J Rheumatol - August 15, 2022 Category: Rheumatology Authors: Charis F Meng Diviya A Rajesh Deanna P Jannat-Khah Bridget Jivanelli Vivian Bykerk Source Type: research